Blood Tests to Exclude Polycythemia Vera
To exclude polycythemia vera, test for JAK2 V617F mutation (or JAK2 exon 12 mutation if V617F is negative) combined with serum erythropoietin level. These two tests form the cornerstone of the diagnostic workup and can effectively rule out PV when both are negative/normal 1.
Diagnostic Algorithm
Initial Blood Work
Start with a complete blood count (CBC) to confirm erythrocytosis. According to WHO criteria, PV requires:
- Hemoglobin ≥18.5 g/dL in men or ≥16.5 g/dL in women 1
- Or hemoglobin ≥17 g/dL in men or ≥15 g/dL in women with a sustained increase of ≥2 g/dL from baseline 1
Key Molecular Test: JAK2 Mutation
JAK2 V617F mutation testing is the single most important test to distinguish PV from secondary causes of erythrocytosis 1. This mutation is present in more than 90-95% of PV patients 1, 2. The mutation is absent in secondary polycythemia (from smoking, sleep apnea, chronic hypoxia) and relative polycythemia 3.
- If JAK2 V617F is negative, test for JAK2 exon 12 mutations, which account for most remaining PV cases 1
- These mutations provide proof of clonal proliferation and eliminate consideration of reactive processes 1
Serum Erythropoietin Level
Serum erythropoietin below the reference range for normal is a minor diagnostic criterion for PV 1, 3. This test helps differentiate:
- PV: Low/subnormal erythropoietin (autonomous red cell production)
- Secondary erythrocytosis: Elevated erythropoietin (appropriate response to hypoxia or inappropriate tumor production)
WHO Diagnostic Criteria Framework
To exclude PV, you need to demonstrate the patient does NOT meet these criteria 1:
Major Criteria (both required):
- Elevated hemoglobin/hematocrit as above
- Presence of JAK2 V617F or JAK2 exon 12 mutation
Minor Criteria (need 1 if both major present, or 2 if only first major present):
- Bone marrow biopsy showing hypercellularity with panmyelosis
- Serum erythropoietin below normal range
- Endogenous erythroid colony formation in vitro
Practical Approach to Exclusion
If JAK2 mutations are negative AND erythropoietin is normal or elevated, PV is effectively excluded 3. At this point, focus shifts to identifying secondary causes:
- Chronic hypoxia (COPD, sleep apnea, high altitude)
- Smoking
- Renal pathology (tumors, cysts)
- Medications (androgens, SGLT2 inhibitors, erythropoietin-stimulating agents)
- Relative polycythemia from plasma volume contraction 4
Important Caveats
Iron deficiency can mask PV by lowering hemoglobin levels below diagnostic thresholds 1, 3. If clinical suspicion remains high despite borderline hemoglobin with iron deficiency, recheck after iron replacement 1.
Look for associated findings that increase PV likelihood:
- Thrombocytosis (present in 53% of PV patients) 2
- Leukocytosis (present in 49%) 2
- Splenomegaly (36%) 2
- Pruritus, especially after warm baths (33%) 2
The combination of JAK2 V617F positivity with both major criteria captures more than 97% of PV cases 3, making these the most efficient tests for both diagnosis and exclusion.
If erythrocytosis is isolated (no leukocytosis or thrombocytosis), prioritize excluding secondary and hereditary causes before extensive genetic testing 4. However, if accompanied by other cytopenias, JAK2 testing should be performed early 4.